" Longer-term, I think it could be related to bioengineering and China. Consider Pike's previous involvement with AOB, and Steve's association with Proteonomix. And note PROT's developing relationship with Sinoquest and China Biopharma. Even the related interests of Parlux and Azurel could be considered in an ancillary footnote."
As far as I saw:
1. Pike made a relatively small investment in AOB in 2007.
2. Steve (I guess you mean Moskowitz?) was a Proteonomix Director in 2007. Proteonomix's most recent 10Q, filed 11/13/09, shows sales of $127,000 for the first 9 months of 2009.
3. The developing relationship with Sinoquest and China Biopharma. Excerpts from PROT's 10/A dated 1/19/10 (last Tuesday):
"In January, 2009, we entered into an agreement with two China-based companies, China Biopharma, Inc., which distributes pharmaceuticals and cosmetics in China, and Sinoquest Investment Ltd., which controls several pharmaceutical and cosmetic distribution companies in China."
"The purchasers were obligated to purchase 10,000 units per year commencing the date of the first order. "
"We received the first order for the materials for the production of 10,000 kits at $100 per unit. Pursuant to the terms of the purchase order, we had to demonstrate our financial ability to manufacture the raw materials for 50,000 units before payment for the first order would be made. We were unable to demonstrate our financial ability to manufacture 50,000 kits and the purchase order expired."
The original order was replaced with an oral purchase order.
4. Parlux and Azurel? From the same Proteonomix filing made last Tuesday:
Item 1. Business.
Our predecessor, Azurel, Ltd. (“Azurel”), was incorporated in 1995 and had been a public company marketing a line of fragrances and cosmetics under proprietary names such as “Privilege” and “Benendre.” On February 2, 2001, Azurel filed a voluntary petition for protection from creditors under Chapter 11 in the United States Bankruptcy Court for the District of New Jersey, Newark. Azurel was discharged from bankruptcy on December 28, 2005. Azurel traded on Nasdaq from January, 2001 to May, 2003, on the OTC Bulletin Board from May, 2003 to January, 2006, and on the Pink Sheets from February, 2006 to September, 2006 under the symbol AZUR, from September, 2006 to August, 2008 under the symbol NHGI and from August, 2008 to the present under the symbol PROT. Azurel deregistered from its duty to file reports with the Commission on January 30, 2006.
On September 12, 2006, Azurel acquired National Stem Cell, Inc., a Delaware corporation (“National Stem Cell”), as a wholly-owned subsidiary and Azurel changed its name to National Stem Cell Holding, Inc. (“National Stem Cell Holding”) following the acquisition. The acquisition of National Stem Cell included the acquisition of its subsidiary, The Sperm Bank of New York, Inc. (“SBNY”). In this transaction, Azurel’s common stock was reverse split 1:37. In August, 2008, National Stem Cell Holding reverse split its stock 1:10 and changed its name to Proteonomix, Inc. (“Proteonomix”).
I'm concerned that this is merely a perpetuation of the ongoing purchase/sale/reverse merger/blank check shuffle that emphasizes the exchange of shares versus the sale of product. Please help me understand how any of the above translates to "Whether Pike's interest is strictly in SpongeTech, or beyond, this could get real big, real fast" based on these connections.
